In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.
Eye Care Insider
Claim This Podcastby Joshua Mali, MD
4.2(5 reviews)
26 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.
Language
🇺🇲
Publishing Since
8/25/2020
23 verified contact emails on file for Eye Care Insider
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
May 1, 2023
Corneal Rejuvenation with Trefoil Therapeutics
<p class="MsoNormal">In this episode, I discuss corneal disease and treatments with <strong>David Eveleth, PhD,</strong> the founder, president and CEO of Trefoil Therapeutics.</p> <p class="MsoNormal">Brought to you by Alcon</p> <p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Welcome to another exciting episode of Eye Care insider <strong>:14</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Intro David Eveleth, PhD <strong>:47</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Eveleth’s background <strong>1:05</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What’s the treatment landscape now for corneal diseases and where are we falling short for patients? <strong>2:59</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->The origins of Trefoil Therapeutics <strong>7:27</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->FGF-1: Is it just important in the endothelium or is it also important in the epithelium? <strong>11:47</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What is your current lead investigational candidate? <strong>14:01</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->When do you expect another read out of clinical data? <strong>21:47</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->An adjunctive therapy with cataract surgery <strong>18:27</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What is the timeline of administration to patients? <strong>19:24</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->When do you expect a readout of clinical data? <strong>20:49</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Is it possible to use this also for the epithelium? <strong>21:39</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? <strong>24:07</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit <a href= "http://www.trefoiltherapeutics.com">www.trefoiltherapeutics.com</a> <strong>25:53</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Corneal disease can be fixed and better vision is possible <strong>26:44</strong></p> <p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Thanks for listening <strong>27:04</strong></p> <p class="MsoNormal">We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.</p> <p class="MsoNormal"><strong>David Eveleth, PhD,</strong> is the president and CEO of Trefoil Therapeutics.</p> <p class="MsoNormal"><strong>Disclosures:</strong> Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.</p>
April 7, 2023
EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System
<p class="MsoNormal">In this episode, I chat with <strong>Nancy Lurker,</strong> CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.</p> <p class="MsoNormal">Brought to you by Alcon</p> <p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Welcome to another exciting episode of Eye Care insider <strong>:13</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Intro Nancy Lurker <strong>:22</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Lurker’s background <strong>:58</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->EyePoint Pharmaceuticals: the origin and transition <strong>2:29</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Yutiq and long-acting drug delivery systems <strong>6:07</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Additional indications for Yutiq <strong>8:30</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What is the key factor in delivering this longer durability? <strong>16:13</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Any consideration of looking at superiority of visual acuity and anatomical OCT gains? <strong>21:47</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? <strong>24:19</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Investor information and neural protection data <strong>29:01</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->What is the most important issue that the field of ophthalmology is currently facing? <strong>30:38</strong></p> <p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Thanks for listening <strong>32:37</strong></p> <p class="MsoNormal">We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.</p> <p class="MsoNormal"><strong>Nancy Lurker</strong> is the board director and CEO of EyePoint Pharmaceuticals.</p> <p class="MsoNormal"><strong>Disclosures:</strong> Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.</p>
March 21, 2023
Samsara Vision’s SING IMT: Game Changer for the Advanced AMD Patient
<p class="MsoNormal">In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with <strong>Rebecca Kammer, OD, PhD</strong>.</p> <p class="MsoNormal">Brought to you by Alcon</p> <p class="MsoListParagraphCxSpFirst" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Welcome to another exciting episode of Eye Care insider <strong>:14</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Intro for Rebecca Kammer, OD, PhD <strong>:27</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Dr. Kammer’s background <strong>1:28</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Defining late-stage AMD patients and treatments available <strong>5:11</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->The SING IMT <strong>9:46</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]--><a href= "https://www.oraconnects.com/find-a-trial-amd-old/">US Concerto Study Website</a> – to learn more about the study <strong>13:13</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Visual acuity and the SING IMT <strong>13:48</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->US trial, recruitment and patient eligibility <strong>17:18</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Contact toll-free <strong>1-866-393-3767</strong> discuss eligibility, participation and questions <strong>20:39</strong></p> <p class="MsoListParagraphCxSpMiddle" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->SING IMT as an option for patients <strong>22:55</strong></p> <p class="MsoListParagraphCxSpLast" style= "text-indent: -.25in; line-height: 106%; mso-list: l0 level1 lfo1;"> <!-- [if !supportLists]--><span style= "font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span> <!--[endif]-->Thanks for listening <strong>27:30</strong></p> <p class="MsoNormal">We’d love to hear from you! Send your comments/questions to Dr. Mali at <a href= "mailto:eyecareinsider@healio.com">eyecareinsider@healio.com</a>. Follow us on Twitter <a href= "https://twitter.com/HRheuminations">@Healio_OSN</a>. You can reach Dr. Kammer at <a href= "mailto:rkammer@samsaravision.com">rkammer@samsaravision.com</a>.</p> <p class="MsoNormal"><strong>Rebecca Kammer, OD, PhD,</strong> is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.</p> <p class="MsoNormal"><strong>Disclosures:</strong> Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.</p>
26 total episodes available
Deep-dive analytics for Eye Care Insider
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Eye Care Insider?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.